ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 14 (1) 73-80    DOI: 10.1677/erc.1.01312
Copyright © 2007 by the Society for Endocrinology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rolland, P.
Right arrow Articles by Spendlove, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rolland, P.
Right arrow Articles by Spendlove, I.

The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease

 Phil Rolland, Zahra Madjd, Lindy Durrant, Ian O Ellis1, Rob Layfield2 and Ian Spendlove

Academic and Clinical Department of Oncology, Institute of Infections and Immunity, University of Nottingham, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham NG5 1PB, UK
1 Department of Histopathology, University Hospitals Nottingham, Nottingham NG5 1PB, UK
2 School of Biomedical Sciences, University of Nottingham, Nottingham NG7 2UH, UK

(Requests for offprints should be addressed to I Spendlove; Email: ian.spendlove{at}nottingham.ac.uk)

p62 is a multi-functional protein, which induces nuclear factor-{kappa}B (NF{kappa}B) activation through multiple upstream signalling pathways, including those triggered by the epidermal growth factor (EGF) family of receptors. We hypothesised that p62 overexpression increased EGF family receptor expression and worse outcome in breast cancer would be associated. We stained a tissue microarray representing 523 breast cancers using a commercial guinea pig anti-human p62 sera and standard immunohistochemical methods to address this. Out of n = 106 tumours, 20.3% stained positively. p62 expression correlated with grade (P = 0.010) and distant metastasis (P = 0.04) and EGF receptor (EGFR) (P = 0.012), HER2 (P = 0.016), HER3 (P = 0.007) and HER4 (0.002) expressions. Though expression correlated with reduced 5-year survival (58.5 vs 73.6%), there was no association with overall disease specific survival. p62 expression may represent a marker of activation of the NF{kappa}B pathway.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Endocrinology.